Dartmouth Center of Cancer Nanotechnology Excellence
Menu

DCCNE Funding Opportunities

2012 DOD Congressionally Directed Medical Research Programs (CDMRP) Announcements

The Fiscal Year 2012 (FY12) Defense Appropriations Act provides research funding for the peer reviewed programs managed by the Department of Defense (DOD) office of Congressionally Directed Medical Research Programs (CDMRP).

Funding opportunities are available from the following programs:

  • Breast Cancer Research Program
    • Clinical Translational Research Award
    • Era of Hope Scholar Award
    • Idea Award
    • Impact Award
    • Innovator
    • Postdoctoral Fellowship Award
    • Transformative Vision Award
  • Ovarian Cancer Research Program
    • Ovarian Cancer Academy Award—Early-Career Investigator
    • Pilot Award
    • Synergistic Translational Leverage Award
    • Teal Innovator Award
  • Peer Reviewed Medical Research Program
    • Investigator-Initiated Research Award

Detailed descriptions of each of the funding opportunities, evaluation criteria, and submission requirements can be found in the respective Program Announcements. Each Program Announcement is available electronically for downloading from the Grants.gov website, the CDMRP website, and the CDMRP eReceipt System.

All current and previous funding opportunities are available on the CDMRP website. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Nanotechnology Funding Opportunities from the National Cancer Institute

The National Cancer Institute is currently soliciting proposals for contract funding opportunities in cancer nanotechnology through the SBIR & STTR Programs:

Learn more about cancer nanotechnology funding opportunities.

Nanoscience and Nanotechnology in Biology and Medicine (R01)

Application Receipt/Submission Date(s): Multiple dates, see announcement.

Funding Opportunity Announcement (FOA) Number: PA-11-148

National Cancer Institute (NCI) is interested in the development of, but not limited to, the following research areas:

  1. Nanotechnology-based diagnostic assays and imaging devices that would provide significantly improved sensitivity, specificity and selectivity in cancer detection;
  2. Nanotechnology-based in vivo drug delivery techniques allowing for a significant increase in therapeutic index of the treatment;
  3. Cancer theranostics with improved targeting, biocompatibility and imaging contrast capability;
  4. Paradigm-shifting approaches to nanomaterials fabrication for cancer applications that could lead, e.g., to improved control of size, shape, surface characteristics, and lower fabrication costs.
NCI's specific areas of focus and application include:
  1. Nanotechnology-based techniques enabling understanding, prevention, detection, and elimination of metastases,
  2. Nanotechnology-based techniques enabling understanding and overcoming of multi-drug resistance phenomenon (MDR),
  3. Nanotechnology tools and devices aimed specifically at monitoring of the tumor mecroenvironment, its heterogeneity, and its changes during tumorogenesis,
  4. Nanotechnology-based techniques for improved immunotherapies,
  5. Nanotechnology tools and devices which can penetrate cellular barriers that may limit devices accessibility to intended targets (notably including the blood-brain-barrier),
  6. Nanotechnology-based techniques allowing for capture, monitoring, and characterization of circulating tumor cells (CTCs),
  7. Methodologies for predictive modeling and understanding of nanomaterials' pharmacokinetics and pharmacodynamics in in-vivo environment.

Nanoscience and Nanotechnology in Biology and Medicine (R21)

Application Receipt/Submission Date(s): Multiple dates, see announcement.

Funding Opportunity Announcement (FOA) Number: PA-11-149

National Cancer Institute (NCI) is interested in the development of, but not limited to, the following research areas:

  1. Nanotechnology-based diagnostic assays and imaging devices that would provide significantly improved sensitivity, specificity and selectivity in cancer detection;
  2. Nanotechnology-based in vivo drug delivery techniques allowing for a significant increase in therapeutic index of the treatment;
  3. Cancer theranostics with improved targeting, biocompatibility and imaging contrast capability;
  4. Paradigm-shifting approaches to nanomaterials fabrication for cancer applications that could lead, e.g., to improved control of size, shape, surface characteristics, and lower fabrication costs.
NCI's specific areas of focus and application include:
  1. Nanotechnology-based techniques enabling understanding, prevention, detection, and elimination of metastases,
  2. Nanotechnology-based techniques enabling understanding and overcoming of multi-drug resistance phenomenon (MDR),
  3. Nanotechnology tools and devices aimed specifically at monitoring of the tumor mecroenvironment, its heterogeneity, and its changes during tumorogenesis,
  4. Nanotechnology-based techniques for improved immunotherapies,
  5. Nanotechnology tools and devices which can penetrate cellular barriers that may limit devices accessibility to intended targets (notably including the blood-brain-barrier),
  6. Nanotechnology-based techniques allowing for capture, monitoring, and characterization of circulating tumor cells (CTCs),
  7. Methodologies for predictive modeling and understanding of nanomaterials' pharmacokinetics and pharmacodynamics in in-vivo environment.

Image Guided Drug Delivery in Cancer (R01)

Program Announcement (PA) Number: PA-09-253

See the NIH website for details.